Nicole A. Doria‐Rose

National Institutes of Health

Papers

2

Total Citations

29

H-Index

2

About

Nicole A. Doria-Rose is a leading immunologist whose research focuses on the development of broadly neutralizing antibodies (bnAbs) against viral pathogens, particularly HIV-1 and coronaviruses. Her work has been instrumental in advancing our understanding of antibody-mediated immunity and vaccine design. One of her major contributions is the development of the "High throughput HIV-1 microneutralization assay," a cornerstone technique for evaluating the potency and breadth of HIV-1 Envelope-directed antibodies. This assay, cited over 20 times, has become a standard tool in the field, enabling rapid screening of neutralizing antibodies for vaccine and therapeutic development. More recently, Doria-Rose has applied her expertise to the COVID-19 pandemic, leading the isolation and characterization of cross-neutralizing coronavirus antibodies from recovered patients. Her 2021 study on this topic, though newly published, highlights her ability to pivot her HIV research framework to address emerging global health threats. Through these efforts, she has significantly impacted the rational design of vaccines and immunotherapies, cementing her reputation as a key figure in viral immunology.

Research Focus

Key Achievements

2
H-Index
2
Papers
29
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
High throughput HIV-1 microneutralization assay
21 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 35
🏛 Institutions: National Institutes of Health

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 16 days ago